Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease
Zoe Boyer‐Díaz, Peio Aristu-Zabalza, María Andrés‐Rozas, Claude Robert, Martí Ortega‐Ribera, Anabel Fernández‐Iglesias, Pierre Broqua, Jean-Louis Junien, Guillaume Wettstein, Jaime Bosch, Jordi Gracia‐Sancho
Topics & Concepts
MedicineAgonistPortal hypertensionChronic liver diseaseInternal medicineLiver fibrosisGastroenterologyHepatic fibrosisFibrosisLiver diseaseReceptorCirrhosisLiver Disease Diagnosis and TreatmentPeroxisome Proliferator-Activated ReceptorsLiver Disease and Transplantation